This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 1995:66:143-80.

doi: 10.1016/s0065-230x(08)60253-5.

p53: a cell cycle regulator activated by DNA damage

G Selivanova¹, K G Wiman

Affiliations

PMID: 7793313
DOI: 10.1016/s0065-230x(08)60253-5

Review

p53: a cell cycle regulator activated by DNA damage

G Selivanova et al. Adv Cancer Res. 1995.

. 1995:66:143-80.

doi: 10.1016/s0065-230x(08)60253-5.

Authors

G Selivanova¹, K G Wiman

Affiliation

¹ Microbiology and Tumor Biology Center, Karolinska Institute, Stockholm, Sweden.

PMID: 7793313
DOI: 10.1016/s0065-230x(08)60253-5

No abstract available

PubMed Disclaimer

Similar articles

[TP53 tumor suppressor gene: 20 years (and ten thousand mutations) later].
Hainaut P. Hainaut P. Bull Cancer. 2000 Jan;87(1):11-8. Bull Cancer. 2000. PMID: 10673626 French. No abstract available.
[Tumor suppressor gene p53].
Tokino T. Tokino T. Nihon Rinsho. 1996 Apr;54(4):960-4. Nihon Rinsho. 1996. PMID: 8920657 Review. Japanese.
The molecular perspective: p53 tumor suppressor.
Goodsell DS. Goodsell DS. Oncologist. 1999;4(2):138-9. Oncologist. 1999. PMID: 10337384 No abstract available.
The role of p53-target genes in human cancer.
Tokino T, Nakamura Y. Tokino T, et al. Crit Rev Oncol Hematol. 2000 Jan;33(1):1-6. doi: 10.1016/s1040-8428(99)00051-7. Crit Rev Oncol Hematol. 2000. PMID: 10714958 Review.
Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.
Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Greenblatt MS, et al. Cancer Res. 1994 Sep 15;54(18):4855-78. Cancer Res. 1994. PMID: 8069852 Review. No abstract available.

See all similar articles

Cited by

New p53-based anti-cancer therapeutic strategies.
Wiman KG. Wiman KG. Med Oncol. 1998 Dec;15(4):222-8. doi: 10.1007/BF02787204. Med Oncol. 1998. PMID: 9951684 Review.
P53 mutations associated with breast, colorectal, liver, lung, and ovarian cancers.
Lasky T, Silbergeld E. Lasky T, et al. Environ Health Perspect. 1996 Dec;104(12):1324-31. doi: 10.1289/ehp.961041324. Environ Health Perspect. 1996. PMID: 9118874 Free PMC article.
T cells from baxalpha transgenic mice show accelerated apoptosis in response to stimuli but do not show restored DNA damage-induced cell death in the absence of p53.
Brady HJ, Salomons GS, Bobeldijk RC, Berns AJ. Brady HJ, et al. EMBO J. 1996 Mar 15;15(6):1221-30. EMBO J. 1996. PMID: 8635454 Free PMC article.
CD3-epsilon overexpressed in prothymocytes acts as an oncogene.
Wang B, She J, Salio M, Allen D, Lacy E, Lonberg N, Terhorst C. Wang B, et al. Mol Med. 1997 Jan;3(1):72-81. Mol Med. 1997. PMID: 9132282 Free PMC article.
Li-Fraumeni syndrome fibroblasts homozygous for p53 mutations are deficient in global DNA repair but exhibit normal transcription-coupled repair and enhanced UV resistance.
Ford JM, Hanawalt PC. Ford JM, et al. Proc Natl Acad Sci U S A. 1995 Sep 12;92(19):8876-80. doi: 10.1073/pnas.92.19.8876. Proc Natl Acad Sci U S A. 1995. PMID: 7568035 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal